Sensitive content

This media may contain sensitive content.

Loading video...

Video Failed to Load

Go Home

Reporting in for the initial processing procedures… Stage 1 commencing… ⛓️🔝: Nex 1068 #rubberdrone #rubberfetish #rubberkink #rubberkinkster #rubbergear #fullrubbercoverage #gearhead

0 Comments

No comments available

Comments from the original post will appear here

Related Videos

PHOTON COUNTING CT is NOT a better CT It is a NEW imaging modality Photon Counting CT (PCCT) represents a transformative leap in medical imaging, not only as a molecular imaging modality but also as a technology offering ultra-high resolution and functional imaging capabilities. It is fundamentally more than just an enhanced version of traditional CT—PCCT introduces new ways of seeing and understanding the human body, providing critical insights at the molecular, structural, and functional levels. This positions PCCT as a unique imaging modality that requires a fresh approach to technical implementation, operational workflows, and financial planning. Despite the larger upfront investment, PCCT’s ability to drastically reduce downstream healthcare costs makes it a highly valuable investment in the long run. 1. Technical Innovations • Molecular Imaging and Energy Discrimination: Unlike traditional CT, which simply measures the total absorbed energy, PCCT counts individual X-ray photons and differentiates their energy levels. This allows for precise molecular imaging, revealing the composition of tissues and materials at a biochemical level. By distinguishing between different tissue types and contrast agents, PCCT opens up new diagnostic possibilities, such as identifying molecular biomarkers in tumors or distinguishing between stable and unstable plaque in coronary arteries. This capability shifts the focus of imaging from purely anatomical to both anatomical and molecular, offering more comprehensive diagnostic information. • Ultra-High Spatial Resolution: PCCT features significantly smaller detector elements compared to conventional CT scanners, allowing for ultra-high resolution imaging. This means clinicians can visualize fine structures such as microcalcifications in arteries, small lesions in soft tissues, or the intricate architecture of bones. This level of detail was previously unattainable with traditional CT. When combined with molecular imaging, this ultra-high resolution allows for the precise localization and characterization of disease at very early stages, which is essential for early diagnosis and intervention. • Functional Imaging Capabilities: PCCT also excels as a functional imaging modality. By capturing energy-resolved information, PCCT can provide insights into tissue functionality and dynamic physiological processes. For instance, it can detect changes in blood flow, tissue perfusion, and oxygenation without the need for additional contrast agents or scans. This functionality allows for real-time assessment of physiological processes, making it particularly valuable in cardiology, oncology, and neurology for evaluating organ function and monitoring disease progression. • Reduced Noise and Artifact Reduction: Photon-counting technology dramatically reduces electronic noise and imaging artifacts, such as beam hardening, resulting in clearer and more accurate images. The ability to deliver ultra-high resolution images with minimal artifacts improves diagnostic accuracy, reducing the need for repeat scans and ensuring that even subtle abnormalities are detected. 2. Operational Considerations • New Workflow for Molecular, High-Resolution, and Functional Imaging: The integration of molecular, ultra-high resolution, and functional imaging into routine clinical workflows introduces complexity that requires adaptation. Radiologists and technicians need specialized training to interpret and analyze multi-energy datasets that include molecular and functional information. PCCT produces a vast amount of detailed data, requiring clinicians to adopt new imaging protocols and refine their diagnostic approaches to fully leverage its capabilities. • Post-Processing and Data Management: PCCT generates richer, more complex datasets, which necessitates advanced post-processing tools and data management systems. Existing PACS and imaging software may not be equipped to handle such large volumes of data or to process functional and molecular information effectively. This means healthcare institutions must invest in robust IT infrastructure, including upgraded software and storage solutions, as well as provide additional training for staff on new imaging analysis techniques. • Revised Clinical Protocols: The molecular, functional, and ultra-high resolution imaging capabilities of PCCT will likely prompt changes in clinical protocols. For instance, the need for contrast agents may be reduced, simplifying patient preparation and decreasing the risk of adverse reactions. Additionally, the ability to monitor physiological functions in real-time through functional imaging could lead to more dynamic diagnostic procedures, such as assessing the effectiveness of interventions or treatments in real-time. 3. Financial Impact • Higher Initial Investment: PCCT systems are more expensive than traditional CT scanners due to their advanced technology, which includes photon-counting detectors and the computational power required for high-resolution, molecular, and functional imaging. While this upfront cost is significant, it is crucial to view it in the broader context of the downstream benefits and cost reductions that PCCT offers. • Downstream Cost Reductions: Although the initial capital investment is higher, PCCT’s ability to combine molecular, functional, and ultra-high resolution imaging leads to substantial reductions in downstream healthcare costs. Its superior diagnostic accuracy minimizes the need for follow-up tests, repeat scans, or invasive diagnostic procedures, such as diagnostic coronary angiographies. For example, in cardiology, PCCT can precisely differentiate between types of coronary plaque, reducing the need for invasive procedures to assess risk. • Lower Overall Healthcare Expenditures: By enabling earlier, more accurate diagnoses, PCCT can reduce the overall cost of patient care. Early detection of disease, particularly through its molecular and functional imaging capabilities, allows for more targeted treatments, potentially preventing the need for more aggressive and expensive interventions down the line. For instance, early-stage tumor detection via molecular imaging could lead to less invasive treatments, reducing hospital stays and improving patient outcomes, ultimately driving down healthcare costs. • Increased ROI Through Enhanced Patient Outcomes: Over time, the combination of molecular, functional, and ultra-high resolution imaging enhances diagnostic precision, which translates into better patient outcomes. Improved diagnostic accuracy reduces the incidence of unnecessary procedures, minimizes treatment delays, and results in more personalized and effective care. This leads to increased patient satisfaction, better healthcare outcomes, and greater patient throughput—all factors that improve the institution’s return on investment (ROI). • Competitive Advantage and New Revenue Streams: By adopting PCCT, healthcare institutions position themselves at the forefront of advanced imaging technologies. The ability to offer molecular, functional, and ultra-high resolution imaging creates a competitive advantage, attracting more complex and high-value cases. This can boost the institution’s reputation for excellence in diagnostics, leading to increased referrals, new patient populations, and expanded revenue opportunities. Summary Photon Counting CT (PCCT) is not just an evolution of existing CT technology—it is a molecular, ultra-high resolution, and functional imaging modality that fundamentally transforms the diagnostic landscape. Its ability to capture detailed molecular data, visualize minute anatomical structures with ultra-high resolution, and provide real-time functional imaging opens new possibilities for earlier and more precise diagnoses. While the financial investment in PCCT is larger, the reduction in downstream healthcare costs through improved diagnostic accuracy, fewer unnecessary interventions, and earlier disease detection far outweighs the initial expense. For institutions committed to advancing patient care and improving long-term financial outcomes, PCCT is an essential investment in the future of medical imaging. The video attached shows a patient accessing the Hospital for ACS. PCCT can provide ALL the imaging information of the concurrent imaging modalities (CXR, CAG, Echo, CMR) that you see around it... that's a lot! #PhotonCountingCT #MolecularImaging #UltraHighResolution #FunctionalImaging #FutureOfImaging #AdvancedMedicalImaging #EarlyDiseaseDetection #InnovativeCT #CuttingEdgeHealthcare #PrecisionDiagnostics #HealthcareInnovation #MedicalTechnology #CostEffectiveImaging #NextGenCT #PatientCareRevolution

Dr. Filippo Cademartiri

11,849 views • 1 year ago

𝗘𝘅𝗽𝗹𝗮𝗶𝗻𝗲𝗿: 𝗔𝗻 𝗮𝘁𝘁𝗲𝗺𝗽𝘁 𝗼𝗳 𝗦𝘂𝗸𝗵𝗯𝗶𝗿 𝗦𝗶𝗻𝗴𝗵 𝗕𝗮𝗱𝗮𝗹’𝘀 𝗟𝗶𝗳𝗲 1. 𝗧𝗵𝗲 𝗜𝗻𝗰𝗶𝗱𝗲𝗻𝘁 :- Sukhbir Singh Badal narrowly escaped an assassination attempt at out side of Sri Darbar Sahib (the Golden Temple) while performing Religious Punishment, following a directive from Sri Akal Takht. The attacker, Narayan Singh Chaura, was arrested on the spot. 2. 𝗦𝗲𝗰𝘂𝗿𝗶𝘁𝘆 𝗖𝗼𝗻𝗰𝗲𝗿𝗻𝘀 :- The attempt has raised critical questions: •While the police force successfully prevented the attack, concerns about initial gaps in intelligence and monitoring remain. •The criminal, despite his record, managed to reach a high-security area, indicating potential lapses. 3. 𝗕𝗿𝗼𝗮𝗱𝗲𝗿 𝗜𝗺𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 :- This incident underlines the need for better coordination and vigilance in protecting high-profile figures, especially in sensitive religious spaces. It also adds pressure on law enforcement to reassess and strengthen their protocols. 4. 𝗥𝗲𝗹𝗶𝗴𝗶𝗼𝘂𝘀 𝗣𝘂𝗻𝗶𝘀𝗵𝗺𝗲𝗻𝘁 𝗗𝗲𝗯𝗮𝘁𝗲 :- Days earlier, the Akal Takht issued “Tankhah” (religious punishment) for Akali leaders, including Badal. Some Sikhs believe the punishment was too lenient and divisive. 5. 𝗩𝗶𝗲𝘄 𝗽𝗼𝗶𝗻𝘁 :- Above all, even if someone disagrees with the edict, committing violence is not the answer to stage a protest. #SukhbirBadal #SukhbirBadalAttack

Ravinder Singh Robin

10,438 views • 1 year ago

Today we’re reporting interim Phase 1 clinical data for our REC-617 monotherapy trial – with plans to expand into combination studies in advanced solid tumors. At the AACR Special Conference in Cancer Research, CSO David Hallett shared interim monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. 🔹The interim Phase 1 clinical data for REC-617 included: ▫️Dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagement; ▫️Confirmed partial response (PR) during monotherapy dose-escalation in a patient with platinum-resistant ovarian cancer, treated with 4 lines of prior therapy in an advanced setting, with durable response ongoing after more than 6 months of treatment; ▫️In 4 additional patients, a best response of stable disease (SD) for up to 6 months of treatment. Dr. Hallett noted: “Cell cycle dysregulation and transcriptional 'addiction' are both hallmarks of many aggressive cancers. By inhibiting CDK7, we have the potential to target both mechanisms while fine tuning the therapeutic index.” "These initial findings for REC-617 represent an exciting step forward in the development of CDK7 inhibitors, with a favorable PK/PD profile and a durable confirmed partial response observed in dose escalation in a highly pre-treated patient population," said Najat Khan, Ph.D., Chief R&D Officer and Chief Commercial Officer. “Designed using our AI-powered OS platform, REC-617 reflects our focus on enhancing the therapeutic index to deliver more effective and safer treatment options for patients. We are eager to continue this momentum in dose escalation and to initiate the next phase of the program next year." 👉Learn more: 🔹Join the Update Call: Tomorrow, Tues., Dec. 10 at 8:30am ET, Dr. Hallett and Dr. Khan will hold a live Update Call webcast to present the preliminary data. ▫️Submit questions for the Update Call here: ▫️Tune in to the Update Call here on X or on: LinkedIn: YouTube:

Recursion

11,887 views • 1 year ago

Why the U.S. Securities and Exchange Commission appears to be an even bigger culprit than FINRA in the $MMTLP Fiasco is... The SEC suspected that Brda and Palikaras were guilty of a scheme since at least September 2021. A scheme that according to the SEC, means that neither man should be able to run or presumably be involved with a publicly traded company if found guilty of the charges filed 3 years after the initial subpoenas. So if investors needed to be protected from Brda & Palikaras, how does the SEC justify allowing investors to invest in $MMAT & $MMTLP (TRCH also if the SEC suspected a scheme leading up to the reverse merger), and also making effective the S1 for the Next Bridge Hydrocarbons spin-off? How is it that the SEC has shared oversight of the Options Clearing Corporation (OCC), but they haven't lifted a finger to show the party(s) responsible for getting options started in TRCH directly before the reverse merger? Coincidentally, the SEC has oversight of FINRA, but the SEC hasn't formally addressed the many ways FINRA violated their Rule 6490 when processing the MMTLP Corporate Action, Nor have they lifted a finger to show the party(s) responsible for getting MMTLP tradeable. It's almost like the SEC tried to enact their own form of justice to punish Brda and Palikaras for the alleged scheme, but at the same time, investors were treated like justifiable casualties. This is only part 1 of 5, full video 🎥 linked in the quote post below. Paul Atkins Hester Peirce

Rare DD

10,801 views • 11 months ago

Tencent presents GameGen-O Open-world Video Game Generation We introduce GameGen-O, the first diffusion transformer model tailored for the generation of open-world video games. This model facilitates high-quality, open-domain generation by simulating a wide array of game engine features, such as innovative characters, dynamic environments, complex actions, and diverse events. Additionally, it provides interactive controllability, thus allowing for the gameplay simulation. The development of GameGen-O involves a comprehensive data collection and processing effort from scratch. We collect and build the first Open-World Video Game Dataset (OGameData), amassed extensive data from over a hundred of next-generation open-world games, employing a proprietary data pipeline for efficient sorting, scoring, filtering, and decoupled captioning. This robust and extensive OGameData forms the foundation of our model's training process. GameGen-O undergoes a two-stage training process, consisting of foundation model pretraining and instruction tuning. In the first phase, the model is pre-trained on the OGameData via the text-to-video and video continuation, endowing GameGen-O with the capability for open-domain video game generation. In the second phase, the pre-trained model is frozen, and we fine-tuned using a trainable InstructNet, which enables the production of subsequent frames based on multimodal structural instructions. This whole training process imparts the model with the ability to generate and interactively control content. In summary, GameGen-O represents a notable initial step forward in the realm of open-world video game generation via generative models. It underscores the potential of generative models to serve as an alternative to rendering techniques, which can efficiently combine creative generation with interactive capabilities.

AK

367,128 views • 1 year ago

"𝐑𝐚𝐥𝐞𝐢𝐠𝐡 𝐡𝐚𝐬 𝐬𝐨𝐦𝐞 𝐭𝐡𝐢𝐧𝐠𝐬 𝐢𝐧 𝐩𝐥𝐚𝐜𝐞 𝐭𝐡𝐚𝐭 𝐍𝐚𝐬𝐡𝐯𝐢𝐥𝐥𝐞 𝐝𝐨𝐞𝐬 𝐧𝐨𝐭." Triangle Business Journal is reporting what everyone here in North Carolina and the rest of the baseball world is starting to realize... Nashville may not be the 'front-runner' for MLB expansion in the East after all. And that's not just opinion anymore... - 𝐓𝐡𝐞𝐲'𝐯𝐞 𝐜𝐨𝐦𝐦𝐢𝐭𝐭𝐞𝐝 $𝟏.𝟐𝐁 𝐢𝐧 𝐩𝐮𝐛𝐥𝐢𝐜 𝐟𝐮𝐧𝐝𝐬 to building a brand new NFL stadium for the Tennessee Titans. A stadium which will likely not have hosted a single game by the time MLB Expansion kicks off. - 𝐓𝐡𝐞 𝐥𝐚𝐧𝐝 𝐭𝐡𝐞𝐲 𝐰𝐞𝐫𝐞 𝐭𝐚𝐫𝐠𝐞𝐭𝐢𝐧𝐠 𝐟𝐨𝐫 𝐚 𝐬𝐭𝐚𝐝𝐢𝐮𝐦 𝐢𝐬 𝐨𝐟𝐟 𝐭𝐡𝐞 𝐛𝐨𝐚𝐫𝐝. Nashville just approved the East Bend redevelopment rezoning, which prohibits stadium or arena use on the property. - In an interview on WKRN radio in Nashville, Mayor Freddie O'Connell said in response to landing an MLB expansion team, "𝐖𝐞 𝐝𝐨 𝐧𝐨𝐭 𝐡𝐚𝐯𝐞 𝐚𝐧 𝐌𝐋𝐁 𝐬𝐭𝐚𝐝𝐢𝐮𝐦, 𝐚𝐧𝐝 𝐰𝐞 𝐚𝐫𝐞 𝐧𝐨𝐭 𝐢𝐧𝐭𝐞𝐧𝐝𝐢𝐧𝐠 𝐭𝐨 𝐩𝐮𝐛𝐥𝐢𝐜𝐥𝐲 𝐟𝐢𝐧𝐚𝐧𝐜𝐞 𝐨𝐧𝐞." - 𝐍𝐨 𝐨𝐰𝐧𝐞𝐫 𝐡𝐚𝐬 𝐬𝐭𝐞𝐩𝐩𝐞𝐝 𝐮𝐩, and they've publicly stated they are hoping MLB provides them with one. So if Nashville is not the front-runner, then who is? 𝐈𝐭'𝐬 𝐭𝐢𝐦𝐞 𝐭𝐨 𝐰𝐫𝐚𝐩 𝐲𝐨𝐮𝐫 𝐡𝐞𝐚𝐝 𝐚𝐫𝐨𝐮𝐧𝐝 𝐭𝐡𝐞 𝐧𝐨𝐭𝐢𝐨𝐧 𝐭𝐡𝐚𝐭 𝐑𝐚𝐥𝐞𝐢𝐠𝐡 𝐢𝐬 𝐭𝐡𝐞 𝐟𝐫𝐨𝐧𝐭 𝐫𝐮𝐧𝐧𝐞𝐫 for East Coast MLB expansion. And here's why 👇 𝐖𝐞 𝐡𝐚𝐯𝐞 𝐢𝐭 𝐚𝐥𝐥. - A billionaire owner who just won a Stanley Cup in our market + another with pro sports ownership experience that has publicly stated interest - Multiple land options (w/ districts) ready to go - Bipartisan support in the government which has put forth the initial framework for a stadium funding plan 𝐏𝐥𝐮𝐬, 𝐰𝐞 𝐡𝐚𝐯𝐞 𝐭𝐡𝐞 𝐬𝐭𝐫𝐨𝐧𝐠𝐞𝐫 𝐦𝐚𝐫𝐤𝐞𝐭... - 5M MORE people in our state (largest in the US without MLB) - 1.2M MORE people within 60 miles of our city center - #22 media market in the country; they are #27 - 3 Top-50 media markets in our state; they have 1 It's only a matter of time before people start digging and begin to realize that the past 8 years haven't just been a fun social media campaign... It's been a strategic, non-stop statewide collaboration to bring every single piece of the puzzle together, at the right time, to make it nearly impossible for MLB to say no to expansion in North Carolina. Great reporting from Dane Huffman and the tbj, and we're pretty sure in the coming months you'll hear a WHOLE lot more of the same from outlets all over the country. #RaleighOnDeck #MLB2NC

MLB2NC

12,409 views • 13 days ago